Prevalence of Use of Antihyperglycemic Medications Among Adults Age ≥20 Years With Diagnosed Type 2 Diabetes, U.S., 2015–March 2020
| CHARACTERISTICS | PERCENT (STANDARD ERROR) | ||||||
|---|---|---|---|---|---|---|---|
| Insulin | Sulfonylurea | Biguanide* | Thiazolidinedione | Dipeptidyl Peptidase-4 Inhibitors | GLP-1 Receptor Agonist | SGLT2 Inhibitor | |
| Overall | 22.3 (1.4) | 25.6 (1.6) | 63.1 (1.5) | 4.3 (0.7) | 12.0 (1.4) | 5.5 (0.8) | 5.1 (0.9) |
| Monotherapy† | 6.1 (0.7) | 4.1 (0.7) | 29.5 (1.6) | 0.8 (0.4) | 1.0 (0.4) | 0.1 (0.1) | 0.3 (0.2) |
| Combination therapy‡ | 16.2 (1.3) | 21.5 (1.4) | 33.6 (1.8) | 3.5 (0.5) | 11.0 (1.3) | 5.4 (0.8) | 4.9 (0.9) |
| Age (years) | |||||||
| 20–44 | 21.4 (4.4) | 14.8 (2.7) | 48.1 (4.9) | 3.4 (1.5) | 5.3 (1.8) | 5.1 (1.3) | 5.4 (2.2) |
| 45–64 | 21.3 (2.0) | 23.7 (2.2) | 68.4 (3.2) | 4.2 (1.2) | 14.3 (2.4) | 7.5 (1.2) | 7.8 (1.7) |
| 65–74 | 22.5 (2.2) | 30.4 (3.5) | 69.2 (3.2) | 4.5 (1.4) | 11.0 (2.1) | 3.2 (0.9) | 2.8 (0.7) |
| ≥75 | 25.5 (3.1) | 30.7 (2.9) | 49.9 (2.5) | 4.8 (1.3) | 12.1 (1.9) | 4.1 (1.5) | 1.5 (1.0) |
| Sex | |||||||
| Men | 21.5 (2.0) | 28.0 (1.8) | 67.4 (2.4) | 5.2 (1.1) | 13.2 (1.8) | 5.7 (1.0) | 6.6 (1.5) |
| Women | 23.3 (1.6) | 22.7 (2.2) | 58.0 (2.4) | 3.2 (0.7) | 10.6 (1.5) | 5.2 (1.4) | 3.5 (0.9) |
| Race and ethnicity | |||||||
| Non-Hispanic White | 22.6 (2.1) | 25.7 (2.2) | 65.5 (2.3) | 4.7 (1.2) | 13.6 (2.2) | 6.8 (1.2) | 6.0 (1.4) |
| Non-Hispanic Black | 26.8 (2.4) | 23.5 (2.5) | 55.5 (2.1) | 2.9 (0.8) | 7.9 (1.3) | 5.1 (1.2) | 4.8 (1.0) |
| All Hispanic | 21.4 (2.0) | 23.1 (2.1) | 59.7 (2.6) | 4.2 (1.0) | 9.6 (1.8) | 3.1 (0.7) | 4.2 (1.1) |
| Mexican American§ | 21.2 (2.3) | 25.2 (2.5) | 61.4 (3.7) | 4.5 (1.2) | 10.7 (2.2) | 2.4 (1.1) | 3.8 (1.5) |
Medications are not mutually exclusive; rows add to >100%. Diagnosed type 2 diabetes is self-reported; those with probable type 1 diabetes (insulin use alone and continuous insulin use within one year of diagnosis) were excluded. GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose cotransporter-2.
The biguanide class includes metformin.
Monotherapy: use of one medication
Combination therapy: use of two or more medications
Mexican American is a subset of All Hispanic.
SOURCE: National Health and Nutrition Examination Surveys 2015–March 2020
From: Medication Use and Self-Care Practices in Persons With Diabetes
Diabetes in America is in the public domain of the United States. You may use the work without restriction in the United States.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.